Toxic shock in children with bone and joint infections: a review of seven years of patients admitted to one intensive care unit

D. L. Kerr¹
E. K. Loraas²
A. C. Links³
T. V. Brogan⁴
G. A. Schmale⁵

Abstract

Purpose The objective of this study was to compare the frequency of severe systemic, multi-organ involvement and toxic shock syndrome (TSS) in patients with *Staphylococcus aureus* (SA) and Group A β-haemolytic *Streptococcus pyogenes* (GABS) bone and joint infections.

Methods We retrospectively reviewed patients treated for septic arthritis or osteomyelitis at one children’s hospital between 2002 and 2009. The rates of intensive care unit (ICU) admission for methicillin-sensitive SA (MSSA), methicillin-resistant SA (MRSA) and GABS infections were compared, as were the lengths of stay, number of surgeries, operative procedures and cases of TSS.

Results A total of 16 of 208 patients (7.7%) with culture-positive bone or joint infections were admitted to the ICU for critical illness: more commonly for patients with GABS infection (7/21 or 33%) than those with SA infection (6/132 or 5%) (odds ratio 10.55, 95% confidence interval 3.093 to 35.65, \(p = 0.0002\)). Patients with MRSA infections were significantly more likely to need ICU care than those with MSSA infection (\(p = 0.0009\)). Six of the ICU patients met the Centers for Disease Control and Prevention criteria for TSS. ICU patients with MRSA and GABS bone and joint infections had similar hospital courses: numerous surgeries (mean three per patient); procedures performed (mean 11 per patient); and prolonged hospital stays.

Conclusion We found a greater likelihood of patients developing severe, multi-system involvement with bone and joint infections caused by GABS or MRSA when compared with MSSA. Early aggressive treatment of systemic shock and liberal decompressions of infected joints may limit the sequelae of these serious infections.

Keywords: Group A β-haemolytic *Streptococcus; Staphylococcus aureus; osteomyelitis; septic arthritis; toxic shock syndrome*

Introduction

*Staphylococcus aureus* (SA) and Group A β-haemolytic *Streptococcus pyogenes* (GABS) account for the majority of cases of paediatric bone and joint infections. SA causes 80% to 90% of paediatric bone infections and most joint infections while GABS accounts for approximately 10%.¹⁻⁶ The mortality rate 100 years ago for septic arthritis associated with osteomyelitis in the United States exceeded 50%.⁷ With routine antibiotic treatment, the mortality rate in industrialised nations for septic arthritis dropped to nearly 0.²⁻⁸ However, GABS remains a virulent strain causing high morbidity and mortality. In 1989, Stevens et al⁹ reported a 30% mortality rate and in 1996, Davies et al¹⁰ reported an 81% mortality rate in adults with GABS toxic shock syndromes (TSS), despite aggressive antibiotic and supportive therapies. Mehta et al¹¹ reported a 40% mortality rate in adults and teenage patients admitted to the intensive care unit (ICU) with invasive GABS infections and others have reported an increased incidence of soft-tissue and bone infections and toxic shock caused by GABS.¹²⁻¹⁴ Few published reports of GABS bone and joint infections in children exist.¹⁵⁻¹⁸ TSS, first described in association with SA infection in 1978,¹⁹ was noted to occur most commonly in young women who were using highly absorbent tampons and

¹Dartmouth-Hitchcock Medical Center, Hanover, New Hampshire, USA
²University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
³Kaiser Permanente Tacoma Medical Center, Tacoma, Washington, USA
⁴Seattle Children’s Hospital, Seattle, Washington, USA
⁵University of Washington School of Medicine, Seattle, Washington, USA

Correspondence should be sent to: G. A. Schmale, Seattle Children’s Hospital, M/S MB.10.620, 4800 Sand Point Way NE, Seattle, WA 98145-5005, USA.
E-mail: gschmale@uw.edu
was due to a staphylococcal exotoxin TSST-1. Streptococcal toxic shock syndrome (STSS), associated with GABS infection, was first described in 1987. Both SA and GABS produce an extracellular protein, exotoxin, that acts as a super antigen, activating T-cells and potentially causing massive release of cytokines leading to clinical TSS. GABS also produces other toxins such as the M proteins; however, debate persists as to whether M proteins act as true super antigens. Clinical manifestations of TSS in children include hypotension and multi-organ involvement, with two or more of the following: renal impairment; coagulopathy; abnormal liver function tests; acute respiratory distress syndrome; generalised erythematous macular rash; or soft-tissue necrosis. The objective of this study was to determine the frequency of severe systemic and multi-organ involvement in patients who had bone and joint infections, comparing those with GABS infection with those with SA infection. We hypothesised that the rate of severe systemic involvement would not differ between the two aetiologic agents.

**Patients and methods**

The records of all patients admitted and treated at one children’s hospital for septic arthritis and osteomyelitis between 01 January 2002 and 31 December 2008 were retrospectively reviewed. Those included were diagnosed with septic arthritis or osteomyelitis of the spine or extremities via culture positive synovial fluid or bone aspirates, and/or a purulent appearance of synovial fluid with positive blood cultures, with pain, swelling and irritability related to the aspiration sites. Patients were excluded for the following reasons: age < 30 days or who had remained hospitalised from birth before the onset of their infection; had a likely diagnosis of juvenile arthritis, toxic synovitis, craniofacial osteomyelitis, myositis without joint or bone involvement, cellulitis; or were treated on an outpatient basis. No patient was excluded because of an immune-compromised state due to chemotherapy. Operative reports, progress notes, interim summaries, discharge summaries and laboratory data were reviewed to determine causative organism. ICU admission, the total length of stay, the number of procedures during the index hospitalisation, the number of re-admissions and the total number of surgeries were recorded.

**Statistical analysis**

Variables were summarised using frequencies and percentages for categorical variables, and mean and standard deviation for continuous variables. Fisher’s exact test was used to determine significant difference between categorical variables, and Wilcoxon rank-sum test was used to analyse differences between groups.

Centers for Disease Control and Prevention criteria of STSS and TSS (Tables 1 and 2) were used to determine whether the patients admitted to the ICU with staphylococcal and staphylococcal infections had STSS and TSS, respectively.

Patients with five of six required clinical findings were classified as probable TSS, as described by Lappin and Ferguson.

**Results**

In total, 208 patients were identified with culture-positive septic arthritis and/or osteomyelitis in this seven-year period (Fig. 1). Of those, SA was identified as the causative organism in 131 patients (64%) and GABS in 21 (10%). Other organisms were identified in 52 patients (25%). Of the 126 non-ICU patients with SA, 106 had MSSA bone and joint infections and 20 had MRSA (Table 3). Overall, 16 of 208 patients (8%) with culture-positive bone and joint infections were treated in the ICU for critical illness, 6/131 (5%) with SA and 7/21 (33%) with GABS. Of these 13 patients, there were seven female and six male patients with a mean age of nine years. A significantly higher proportion of those with MRSA (5/25

---

**Table 1.** Centers for Disease Control and Prevention case definition of streptococcal toxic shock syndrome

| Clinical signs | Lab signs |
|---------------|-----------|
| Hypotension: < 90 mmHg systolic or less than 5th percentile by age for children < 16 years | Isolation of group A Streptococcus from a normally sterile site (e.g. blood or cerebrospinal fluid or, less commonly, joint, pleural or pericardial fluid). |
| Multi-organ involvement characterised by two or more of the following: | |
| o renal impairment: creatinine ≥ 2.0 mg/dl for adults or > than twice the upper limit of normal age. In patients with pre-existing renal disease, a greater than twofold elevation over baseline; | |
| o coagulopathy: platelets ≤ 100 000/mm³ or disseminated intravascular coagulation, defined by prolonged clotting times, low fibrinogen level and the presence of fibrin degradation products; | |
| o liver involvement: alanine aminotransferase, aspartate aminotransferase or total bilirubin levels ≥ twice the upper limit of normal for the patient’s age. In patients with pre-existing liver disease, a greater than twofold increase over the baseline level; | |
| o acute respiratory distress syndrome: defined by acute onset of diffuse pulmonary infiltrates and hypoxemia in the absence of cardiac failure or by evidence of diffuse capillary leak manifested by acute onset of generalised oedema, or pleural or peritoneal effusions with hypoalbuminemia; | |
| o a generalised erythematous macular rash that may desquamate; | |
| o soft-tissue necrosis, including necrotising fasciitis or myositis, or gangrene. | |
patients or 20%) were admitted to the ICU for critical illness than those with MSSA (1/106 or < 1%) (p = 0.0009). Overall, GABS patients had a statistically greater likelihood of admission to the ICU than those patients with SA bone and joint infections (odds ratio 10.55, 95% confidence interval 3.093 to 35.65, p = 0.0002), though patients with MRSA infections were just as likely to need ICU care (6/26) as patients with GABS infections (7/21) (p = 0.8).

Length of hospital and ICU stays, number of surgeries and re-admission rates were similar for the MRSA and GABS ICU patients (Table 4). None of the ICU patients had an underlying syndrome or immune-compromised state predisposing them to severe infection.

Five of the seven patients in the streptococcal group met criteria for STSS, whereas only one of the patients in the staphylococcal group met criteria for TSS (p = 0.10).

Table 2. Centers for Disease Control and Prevention definition of staphylococcal toxic shock syndrome

| Clinical signs |
|----------------|
| Fever: temperature greater than or equal to 102.0°F (≥ 38.9°C) |
| Rash: diffuse macular erythroderma |
| Desquamation: one to two weeks after onset of illness, particularly on the palms and soles |
| Hypotension: systolic blood pressure ≤ 90 mmHg for adults or less than 5th percentile by age for children aged less than 16 years; orthostatic drop in diastolic blood pressure ≥ 15 mmHg from lying to sitting, orthostatic syncope or orthostatic dizziness |
| Multisystem involvement (three or more of the following): |
| - gastrointestinal: vomiting or diarrhoea at onset of illness; |
| - mucous membrane: vaginal, oropharyngeal or conjunctival hyperaemia; |
| - renal: blood urea nitrogen or creatinine at least twice the upper limit of normal for laboratory or urinary sediment with pyuria (≥ 5 leukocytes per high-power field) in the absence of urinary tract infection; |
| - hepatic: total bilirubin, alanine aminotransferase enzyme or asparate aminotransferase enzyme levels at least twice the upper limit of normal for laboratory; |
| - hematologic: platelets less than 100 000/mm³; |
| - central nervous system: disorientation or alterations in consciousness without focal neurologic signs when fever and hypotension are absent. |

| Laboratory signs |
|------------------|
| Negative results on the following tests, if obtained: |
| - blood, throat or cerebrospinal fluid cultures (blood culture may be positive for Staphylococcus aureus); |
| - rise in titre to Rocky Mountain spotted fever, leptospirosis or measles. |

Fig. 1 Sites of involvement.
The two patients in the GABS group who did not meet requirements for a diagnosis of STSS also had episodes of severe hypotension requiring inotropic/vasopressor support. No patient with TSS died. As our institution is a tertiary referral centre, many patients with bone and joint infections (1/14 non-ICU patients with GABS and 17/120 non-ICU patients with SA), and most of those also with critical illness (7/8 with GABS and 5/6 with SA), were transferred after initial workup at outside hospitals. Patients ultimately requiring ICU care typically presented with sudden worsening of myalgias and arthralgias, nausea and vomiting, abdominal pain, one or more joints with particular irritability, hypotension and respiratory distress, a markedly elevated C-reactive protein (CRP) (> 15 mg/dL in all cases) and rapidly positive blood culture, though 5/13 had no obvious symptoms of bone or joint involvement when admitted to the ICU for critical illness.

**Discussion**

Although SA more commonly causes osteomyelitis and septic arthritis in children, we found a higher proportion of patients affected with GABS meeting criteria for TSS and requiring ICU hospitalisation for this potentially life-threatening condition. Breaking down SA into MRSA and MSSA, those with MRSA bone and joint infections were significantly more likely to require ICU care than those with MSSA, although the rates of ICU admission for MRSA and GABS were equivalent. Of those admitted to the ICU, there were no significant differences in days hospitalised, number of trips to the operating room or number of re-hospitalisations when comparing MRSA patients with GABS patients.

There are few published reports on GABS and bone and joint infections in children. Ibia et al. described 29 paediatric patients with GABS but did not describe critical illness in any of these patients. Givner et al. reported on 17 children with GABS infections and sepsis, four of whom had soft-tissue, bone or joint involvement. Chris-tie et al. reported on 60 children with GABS bacteraemia, 17 of whom were diagnosed with osteomyelitis and septic arthritis. The mortality rate in that series was 7% overall. In addition, despite prior reports of mortality as high as 80% in patients with STSS, there were no deaths in the six patients with TSS in our study. It is unclear whether this low incidence was due to prompt recognition, early treatment and aggressive care or the small study group.

While other authors have commented upon the epidemiology of invasive GABS infections noting increased recognition and reporting of these critically ill patients, the small number of cases in this series limits our ability to comment on an increase or change in incidence of the disease. Nonetheless, GABS infections typically led to prolonged ICU stays, intubation, hypotension and
coagulopathy, with multiple operating room trips and long-term antibiotic treatment. Unlike previous reports from this institution and others, these infections were not preceded by recent varicella infections.

Though only one of six ICU patients with SA met the criteria for TSS, they were all critically ill, suffering septic shock with multi-organ involvement. Sepsis associated with MRSA infection has been described by others and the frequency of serious bone and joint infection from MRSA infection has been reported to be on the rise. Our more recent experience would support that conclusion, as the percentage of patients with SA musculoskeletal infection (septic arthritis and osteomyelitis) due to MRSA has risen, from 15% (20/131) in this study between 2002 and 2008 to 22% (8/37) for patients with septic arthritis between 2006 and 2013 reported by Telleria et al. This series leads us to recommend prompt evaluation and aggressive treatment of systemic symptoms in paediatric patients with GABS or MRSA septic arthritis or osteomyelitis. For those patients with systemic sepsis and symptoms of toxic shock, the signs of bone and joint infection may be masked by their critical illness. Though identification of the infectious organism often occurs after initiation of the resuscitation of a critically ill patient, a rapidly positive blood culture and a gram stain positive for gram-positive cocci in chains as well as a presenting CRP > 15 mg/dL should herald an increased likelihood for severe systemic illness. In this setting in particular, suspecting the possibility of bone and joint involvement may enable early diagnosis, increasing the effectiveness of aggressive surgical and medical treatments, potentially decreasing ICU stays and reducing the long-term musculoskeletal sequelae of infection.

This study is limited by its retrospective nature and by the small numbers of patients. Almost all of our ICU patients were transferred from outside hospitals and as such we cannot estimate the incidence of such infections.

Patients with GABS bone and joint infections are more likely to develop critical illness requiring ICU admission than those with SA, though patients with MRSA infection are just as likely as those with GABS to require ICU care. GABS septic arthritis and/or osteomyelitis increase the likelihood of TSS when compared with bone and joint infections with SA. Patients with rapidly positive blood cultures, particularly those with gram-positive cocci in chains, and a presenting CRP > 15 mg/dL are at an increased risk of developing septic shock and should be carefully monitored.

Future studies involving larger populations may provide further insight into factors that contribute to the severity of disease in patients with GABS and MRSA bone and joint infections. We urge early and aggressive resuscitation and surgical decompression of bone and joint infections in the critically ill patient to optimise the effectiveness of treatment.

Received 03 April 2017; accepted after revision 22 August 2017.

COMPLIANCE WITH ETHICAL STANDARDS

ACKNOWLEDGEMENT

We would like to thank Dr Viviana Bompadre for her assistance with data analysis, essential to this research.

FUNDING STATEMENT

No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.

OA LICENCE TEXT

This article is distributed under the terms of the Creative Commons Attribution-Non Commercial 4.0 International (CC BY-NC 4.0) licence (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed.

ETHICAL STATEMENT

Ethical Approval: This study was approved by the hospital's Institutional Review Board: IRB #11871.

Informed Consent: Not required.

REFERENCES

1. Faden H, Grossi M. Acute osteomyelitis in children. Reassessment of etiologic agents and their clinical characteristics. Am J Dis Child 1991;145:65-69.
2. Fink CW, Nelson JD. Septic arthritis and osteomyelitis in children. Clin Rheum Dis 1986;12:423-435.
3. Gillespie R. Septic arthritis in childhood. Clin Orthop 1973;96:152-159.
4. Doctor A, Harper MB, Fleisher GR. Group A beta-hemolytic streptococcal bacteremia: historical overview, changing incidence, and recent association with varicella. Pediatr 1995;96:428-433.
5. Green NE, Edwards K. Bone and joint infections in children. Orthop Clin North Am 1987;18:555-576.
6. Karwowska A, Davies HD, Jadav T. Epidemiology and outcome of osteomyelitis in the era of sequential intravenous-oral therapy. Pediatr Infect Dis J 1998;17:1021-1026.
7. Smith T. On the acute arthritis of infants. St. Bartholomew’s Hospital Reports 1874:10:189-204.
8. Bennett OM, Namnyak SS. Acute septic arthritis of the hip joint in infancy and childhood. Clin Orthop Relat Res 1992;281:123-132.
9. Stevens DL, Tanner MH, Winship J, et al. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Eng J Med 1989;321:7.
10. Davies HD, McGee A, Schwartz B, et al. Invasive group A streptococcal infections in Ontario, Canada. N Eng J Med 1996;335:547-554.
11. Mehta S, McGreer A, Low DE, et al. Morbidity and mortality of patients with invasive group A streptococcal infections admitted to the ICU. Chest 2006;130:1679-1686.
12. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Micro Rev 2000;13:470-511.
13. Deighton C. Beta haemolytic streptococci and musculoskeletal sepsis in adults. Ann Rheum Dis 1993;52:483-487.
14. Mascini EM, Janze M, Schellekens JF, et al. Invasive group A streptococcal disease in the Netherlands: Evidence for a protective role of anti-exotoxin A antibodies. J Inf Dis 2000;181:631-638.
15. Christie CD, Havens PL, Shapiro ED. Bacteremia with group A streptococci in childhood. Am J Dis Child 1988;142:559-561.
16. Givner LB, Abramson JS, Wasilauskas B. Apparent increase in the incidence of invasive group A beta-hemolytic streptococcal disease in children. J Pediatr 1991;118:341-346.
17. Ibia EO, Imoisili M, Pikis A. Group A beta-hemolytic streptococcal osteomyelitis in children. Pediatrics 2003;112:e22-e26.
18. Alwattar BJ, Stongwater A, Sala DA. Streptococcal toxic shock syndrome presenting as septic knee arthritis in a 5-year-old child. J Pediatr Orthop 2008;28:124-127.
19. Todd J, Fishaut M, Kapral F, Welch T. Toxic-shock syndrome associated with phage-group-I Staphylococci. Lancet 1978;2:1106-1108.
20. Cone LA, Woodard DR, Schlievert PM, Tomory GS. Clinical and bacteriologic observations of a toxic shock-like syndrome due to Streptococcus pyogenes. N Engl J Med 1987;317:146-149.
21. Lappin E, Ferguson AJ. Gram-positive toxic shock syndromes. Lancet Infect Dis 2009;9:281-290.
22. Breiman RF, Davis JP, Facklam RR, et al. Defining the group A streptococcal toxic shock syndrome. JAMA 1993;269:390-391.
23. No authors listed. CDC. Streptococcal Toxic-Shock Syndrome (STSS) Streptococcus pyogenes) 2010 Case Definition. https://www.cdc.gov/nndss/conditions/streptococcal-toxic-shock-syndrome/case-definition/2010/ (date last accessed 25 August 2017).
24. No authors listed. CDC. Toxic Shock Syndrome (Other than Streptococcal) (TSS) 2011 Case Definition. https://www.cdc.gov/nndss/conditions/toxic-shock-syndrome-other-than-streptococcal/case-definition/2011/ (date last accessed 25 August 2017).
25. Davies HD, McGeer A, Schwartz B, et al. Invasive group A streptococcal infections in Ontario, Canada. N Engl J Med 1996;335:547-554.
26. Stevens DL. The flesh-eating bacterium: what’s next? J Infect Dis 1999;179:536-537.
27. Mills WJ, Mosca VS, Nizet V. Orthopaedic manifestations of invasive group A streptococcal infections complicating primary varicella. J Pediatr Orthop 1996;16:522-528.
28. Tyrrell GJ, Lovgren M, Kress B, Grimsrud K. Varicella-associated invasive group A streptococcal disease in Alberta, Canada—2000-2002. Clin Infect Dis 2005;40:1055-1057.
29. Lee CY, Lee YS, Tsao PC, Jeng MJ, Soong WJ. Musculoskeletal sepsis associated with deep vein thrombosis in a child. Pediatr Neonatol 2016;57:244-247.
30. Shime N, Kawasaki T, Saito O, et al. Incidence and risk factors for mortality in paediatric severe sepsis: results from the national paediatric intensive care registry in Japan. Intensive Care Med 2012;38:192-197.
31. Sarkissian EJ, Gans I, Gunderson MA, et al. Community-acquired Methicillin-resistant Staphylococcus aureus Musculoskeletal Infections: Emerging Trends Over the Past Decade. J Pediatr Orthop 2016;36:323-327.
32. Telleria JJ, Cotter RA, Bompadre V, Steinman SE. Laboratory predictors for risk of revision surgery in pediatric septic arthritis. J Child Orthop 2016;10:247-254.